Bob Gerberich

Magnolia Medical Technologies is on a Mission to ZERO®. Today, we offer healthcare institutions a solution to some of their biggest hidden problems – contamination leading to misdiagnosis of bloodstream infections, including sepsis, which can lead to unnecessary and prolonged antibiotic therapy, and false-positive CLABSIs. Tomorrow, we aspire to create a world free of in-vitro diagnostic errors where rapid, accurate test results improve the lives of patients and providers alike. We know that setting new standards of care is a journey enabled by purposeful innovation, partnerships, and perseverance. As the first step of our journey, we have successfully developed and proven our evidence-based technology platform, Steripath, which we’ve coupled with unparalleled support to change clinical practices and prevent unnecessary patient harm as well as system-wide costs associated with the misdiagnosis of sepsis. Our mission is further enabled by reducing false-positive CLABSIs and leveraging our extensive intellectual property portfolio – consisting of over 100 issued method, apparatus, and design patents and 70+ patent applications pending – to address other important sources of diagnostic error that are harmful to patients and costly to hospitals.